News & Updates

The combination of lenalidomide plus ixazomib in the maintenance treatment of patients with post-transplant myeloma leads to better progression-free survival (PFS) compared with lenalidomide alone in historical controls, according to a study.

First-line treatment with nivolumab – be it in combination with chemotherapy (CT) or with ipilimumab – provided overall survival (OS) benefit and durable responses than CT alone in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to findings from the phase III CheckMate 648 trial.

Patients with head and neck cancer who undergo radiation therapy tend to have persistent opioid use, reveals a study, noting further investigation on early intervention to appropriately wean patients.

For chemoprevention for biliary tract cancers (BTC) and its subtypes, statins appear to confer benefits whereas low-dose aspirin does not, according to a study. Moreover, the addition of low-dose aspirin to statins contributes no further reduction in the risk.

Nutritional status evaluated by the Genetic Nutritional Risk Index (GNRI) can predict complications within 30 days following radical cystectomy (RC), suggests a study.

The first-in-class antibody-drug conjugate mirvetuximab soravtansine (MIRV) shows promising anti-tumour activity in previously treated patients with platinum-resistant ovarian cancer who express high levels of folate receptor alpha (FRα), according to the SORAYA study presented at SGO 2022.